News
OPTN
0.8604
-4.93%
-0.0446
Not Many Are Piling Into OptiNose, Inc. (NASDAQ:OPTN) Stock Yet As It Plummets 42%
The OptiNose, Inc. Share price has fallen by 42% over the last month. The company's price-to-sales ratio of 1.4x is lower than the Pharmaceuticals industry average. Opti nose's revenue growth has been going backwards while other companies have been seeing positive growth. Its P/S ratio is also lower than other Pharmaceuticals companies in the US.
Simply Wall St · 1d ago
Why Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Caterpillar Inc. Fell 6.6% to $339.37 on Thursday. Caterpillar reported better-than-expected first-quarter EPS but missed revenue estimates. Barfresh Food Group, Inc. Shares surged 87.2% after the company reported better than expected results. Chicken Soup for the Entertainment for the Soul Entertainment dropped 75%.
Benzinga · 2d ago
Bristol-Myers Squibb Layoffs 2024: What to Know About the Latest BMY Job Cuts
Bristol-Myers Squibb (NYSE:BMY) announced major cuts to its workforce on Thursday. The biopharmaceutical company will reduce its headcount by 6%, or roughly 2,200 employees. BMY stock is down 7.9% as of Thursday morning. The company is expected to save $1.5 billion per year with these job cuts. There are more stock market news stories worth reading on why stocks are down today. All of the latest Stock Market news for Tuesday is available at InvestorPlace.
Investorplace · 3d ago
Why Are Stocks Down Today?
Major stock indices are down on Thursday with the S&P 500 down 1.43% as of Thursday morning. Meta Platforms (NASDAQ:META) announced its outlook for Q2 2024. The social media company's revenue guidance is below what Wall Street is expecting. New economic data in the U.S. Is also weighing stocks down today. We offer all of the stock market news worth diving into on Thursday.
Investorplace · 3d ago
Why Is OptiNose (OPTN) Stock Up 12% Today?
OptiNose stock is up 12.4% as of Thursday morning. The FDA has approved XHANCE as a treatment for adult patients with chronic rhinosinusitis without nasal polyps. The company also announced its revenue from the treatment for the first three months of 2024. 16 million shares of OPTN stock are trading hands in the wake of the announcement.
Investorplace · 3d ago
Market-Moving News for April 25th
Ultralife shares are trading higher after the company reported better-than-expected Q1 financial results. Cidara Therapeutics shares are also trading higher. Optinose and Ultralife are among the other companies in the biotech sector. The companies are reporting better than expected quarterly results.
Benzinga · 3d ago
Optinose Provides Corporate Updates; Expects To Produce Positive Income From Operations For Full Year 2025
In addition, the Company announced preliminary XHANCE net product revenue of $14.9 million for the three months ended March 31, 2024. The Company expects peak XHance net revenues to exceed $300 million. The company is targeting a specialty audience of mostly ENT and Allergy specialists.
Benzinga · 3d ago
OPTINOSE INC - EXPECTS TO PRODUCE POSITIVE INCOME FROM OPERATIONS (GAAP) FOR FULL YEAR 2025
Reuters · 3d ago
12 Health Care Stocks Moving In Monday's After-Market Session
Nuwellis (NASDAQ:NUWE) stock rose 46.8% to $0.48 during Monday's after-market session. Sensei Biotherapeutics and Cognition Therapeutics among the gainers. Losers include Phio Pharma and Rigel Pharmaceuticals.
Benzinga · 5d ago
Weekly Report: what happened at OPTN last week (0415-0419)?
Weekly Report · 6d ago
OptiNose Falls To US$1.19, But Insiders Sold At Lower Price
OptiNose, Inc. Insiders sold US$184k worth of stock over the past year. The average selling price of US$1.46 is below the current share price. In the last year, the biggest insider sale was US$69k to the CEO of OptiNoses. Opti nose shares have fallen by 11% in the last week. But the company doesn't have any insider buying in the past 12 months. Insiders own 7.8% of optinose shares.
Simply Wall St · 04/16 11:04
Weekly Report: what happened at OPTN last week (0408-0412)?
Weekly Report · 04/15 09:12
Weekly Report: what happened at OPTN last week (0401-0405)?
Weekly Report · 04/08 09:13
Weekly Report: what happened at OPTN last week (0325-0329)?
Weekly Report · 04/01 09:13
Lake Street Remains a Buy on Optinose (OPTN)
TipRanks · 03/26 12:45
Weekly Report: what happened at OPTN last week (0318-0322)?
Weekly Report · 03/25 09:13
Institutional investors may adopt severe steps after OptiNose, Inc.'s (NASDAQ:OPTN) latest 13% drop adds to a year losses
Institutional investors own over 50% of OptiNose, Inc. (NASDAQ:OPTN) The top 7 shareholders of the company own 51% of the stock. The company has a high level of institutional ownership, but this could be due to the nature of the firm's business. The recent share price drop of 13% for Opti nose suggests the company is sensitive to its owners. Optinose is owned by a group of 55% of the company, and has a market capitalization of US$184m. It's important to look at the company's ownership of shares to see who really controls the company.
Simply Wall St · 03/23 14:03
Optinose Is Maintained at Buy by Lake Street
Dow Jones · 03/18 13:44
Optinose Price Target Raised to $4.00/Share From $3.00 by Lake Street
Dow Jones · 03/18 13:44
More
Webull provides a variety of real-time OPTN stock news. You can receive the latest news about Optinose through multiple platforms. This information may help you make smarter investment decisions.
About OPTN
OptiNose, Inc. is a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists. The Company's product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing its Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). XHANCE combines the EDS with a liquid formulation of fluticasone propionate, a well-characterized, second-generation corticosteroid. XHANCE is designed to deliver medication into the high and deep regions of the nasal passages where both nasal polyps and inflamed and swollen membranes can obstruct normal sinus ventilation and drainage. The Company has developed both a liquid delivery EDS and a powder delivery EDS utilizing natural functional behaviors of the upper nasal airways intended to offer better drug deposition.